FDA remains skeptical about booster shots despite new Pfizer data suggesting efficacy declines

Third doses of Pfizer's vaccine appeared to boost antibody levels between five-fold and 12-fold, particularly among older adults, but FDA officials expressed doubt about the need for boosters.

from U.S. Home | Mail Online https://ift.tt/3EpsprU
via Top U.S. Stories